Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rho kinase inhibitor vs prostaglandin analog Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Glaucoma progression at 12 months, defined by anatomic (structural) criteriad · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose computed tomography (LDCT) screening vs no LDCT screening  · healthy adults Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality (2022) · Cochrane | no estimate extracted | NR | No studies |
Collective leadership to improve professional practice, healthcare outcomes and staff well‐being vs usual centralised and hierarchical leadership Professional practice · healthcare professionals Collective leadership to improve professional practice, healthcare outcomes and staff well‐being (2022) · Cochrane | no estimate extracted | NR | No studies |
Collective leadership to improve professional practice, healthcare outcomes and staff well‐being vs usual centralised and hierarchical leadership Health care outcomes · healthcare professionals Collective leadership to improve professional practice, healthcare outcomes and staff well‐being (2022) · Cochrane | no estimate extracted | NR | No studies |
Collective leadership to improve professional practice, healthcare outcomes and staff well‐being vs usual centralised and hierarchical leadership Staff well‐being · healthcare professionals Collective leadership to improve professional practice, healthcare outcomes and staff well‐being (2022) · Cochrane | no estimate extracted | NR | No studies |
Collective leadership to improve professional practice, healthcare outcomes and staff well‐being vs usual centralised and hierarchical leadership Unintended consequences · healthcare professionals Collective leadership to improve professional practice, healthcare outcomes and staff well‐being (2022) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic dopamine antagonist antiemetic medications vs placebo Number of vomiting episodes · adults receiving intravenous opioids Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting (2022) · Cochrane | no estimate extracted | NR | No studies |
Palmitoylethanolamide and luteolin vs no intervention Generic quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Palmitoylethanolamide and luteolin vs no intervention Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention Generic quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Palmitoylethanolamide and luteolin vs no intervention Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Change in sense of taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid spray vs no intervention/placebo Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid spray vs no intervention/placebo Change in sense of taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid spray vs no intervention/placebo Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs control Neurodevelopmental impairment (assessed beyond infancy) · very preterm or very low birth weight infants Synbiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants (2022) · Cochrane | no estimate extracted | NR | No studies |
Synbiotics vs placebo Frequency of defecation (number of stools/week at end of study) · children with chronic constipation without a physical explanation Probiotics for treatment of chronic constipation in children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Continuation vs reduction of polypharmacy Quality of life: clinically important change ‐ not reported · people with schizophrenia Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Continuation vs reduction of polypharmacy Global state: relapse/exacerbations of psychosis ‐ not reported · people with schizophrenia Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia (2022) · Cochrane | no estimate extracted | NR | No studies |
Cervical pessary vs vaginal progesterone Birthweight · women with singleton pregnancies at risk of cervical insufficiency Cervical pessary for preventing preterm birth in singleton pregnancies (2022) · Cochrane | no estimate extracted | NR | No studies |
Cervical pessary vs cervical cerclage Neonatal/paediatric care unit admission · women with singleton pregnancies at risk of cervical insufficiency Cervical pessary for preventing preterm birth in singleton pregnancies (2022) · Cochrane | no estimate extracted | NR | No studies |